Trinity Delta Lighthouse: Redx Pharma
Trinity Delta view: FY22 was another year of delivery, with two wholly-owned Redx assets now in Phase II trials: RXC004 in solid tumours, and RXC007 in IPF, a fibrotic lung disorder. Both are expected to yield key data during 2023, notably H223, which will provide important insights into their respective positioning and commercial potential. In addition, the discovery engine continues to generate pipeline candidates and Redx is aiming to generate three INDs by the end of 2025; this includes RXC008 which is set to enter the clinic in the near-term. Cash of £53.9m at end-September should be sufficient through key value inflection points expected in H223. Our valuation is £458m (or $596m), or 138p per share.Redx Pharma is engaged in drug discovery, pre-clinical development and licensing. The principal activities of the business are the discovery and development of proprietary, small molecule drugs to address areas of high, unmet medical need. Co. is developing a porcupine inhibitor drug candidate, RXC004, as a cancer treatment using in vivo models of pancreatic and gastric cancer. ROCK1/2 inhibitors (known as systemic pan-Rock inhibitors) are known to induce hypotension. Co.'s ROCK inhibitor is designed to only work at the site of action in the gastrointestinal tract and degrades quickly, once absorbed, through enzyme-mediated metabolism in the blood, deeming it a soft inhibitor.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.